BCL2 and acute myeloid leukemia: Consistent with this statement, Fiskus et al. [13] showed that treatment with JQ1 reduced the BRD4 occupancy at the promoters of c-myc, BCL-2, and CDK6 and attenuated the mRNA and protein expression of these associated genes in acute myelogenous leukemia (AML) blast progenitor cells (BPC).